

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 January 2003 (16.01.2003)

PCT

(10) International Publication Number
WO 03/004656 A1

- (51) International Patent Classification: C12N 15/67
- (21) International Application Number: PCT/IB02/03398
- (22) International Filing Date: 8 July 2002 (08.07.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/303,065 6 July 2001 (06.07.2001) US
- (71) Applicants (for all designated States except US): INSTI-
TUT PASTEUR [FR/FR]; 25-28, rue du Docteur Roux,
F-75724 Paris (FR). EVOLOGIC SA [FR/FR]; 89, rue
Henri Rochefort, F-91000 Evry (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MUTZEL, Ruppert
[DE/DE]; An der Steig 19, 78464 Konstanz (DE). MAR-
LIERE, Philippe [FR/FR]; 2, Allée Saint Martin, F-91450
Etioles (FR). MAZEL, Didier [FR/FR]; 79 bis, rue de la
République, F-92150 Suresnes (FR).
- (74) Agent: PERIN, Georges; Cabinet Rinuy-Santarelli, B.P.
237, 14 avenue de la Grande Armée, F-75822 Paris Cedex
17 (FR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KB, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR OBTAINING CELLS WITH NEW PROPERTIES

(57) Abstract: The present invention relates to a method for generating a novel form of life comprising the steps consisting of: a) irreversible alteration of the genome of a microbial clone; b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate; c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a).

WO 03/004656 A1

METHOD FOR OBTAINING CELLS WITH NEW PROPERTIES

- 5 The present invention relates to a method for generating a novel form of life comprising the steps consisting of:
- a) irreversible alteration of the genome of a microbial clone ;
 - b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing
 - 10 selection for a higher and stable proliferation rate;
 - c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a).

- 15 The invention is particularly useful for production of recombinant proteins in bacteria, more particularly in eubacterial hosts. A eubacterial host defective in the genes for Met-tRNAⁱ transformylase and polypeptide deformylase is described which grows in minimal and complex nutrient media at 30°C, 37°C and 42°C with near wild-type rate. In this eubacterium protein synthesis does not require N-formyl
- 20 methionine as the initiator methionine, protein synthesis instead is initiated with unmodified methionine. The absence of peptides which retain N-formyl methionine in this eubacterium makes it particularly suited for the expression of recombinant proteins for pharmaceutical use.

25 Background

Many attempts to drastically modify bacteria for use in industry have failed since such modifications are most of the time lethal or lead to uncompetitive and unstable organisms.

- For example; in eubacteria, peptide synthesis is initiated at methionine start codons which are read by N-formyl methionine tRNA. Prior to translation initiation the methionyl moiety of the charged tRNA is N-formylated by the action of Met-tRNAi transformylase. The N-formyl group is removed from the native protein by
- 5 polypeptide deformylase (E.C. 3.5.1.27), and the initiator methionine can then be cleaved off by methionine aminopeptidase, completing the primer methionine cycle. In contrast, archaea and eukaryotes have a primer methionine cycle devoid of N-formylating and deformylating activities (for review see Mazel et al., 1994, 1996).
- 10 Expression of eukaryotic proteins in eubacterial hosts often results in the production of recombinant proteins that retain an N-terminal formylmethionyl residue (examples include bovine somatotropin [Bogosian et al., 1989]; eel growth hormone [Sugimoto et al., 1990]; human granulocyte colony-stimulating factor [Clogston et al., 1992]; bovine fatty acid-binding protein [Specht, et al., 1994]; bovine cytochrome P450
- 15 [Dong et al. 1995]; *Methanothermus fervidus* histone A [Sandman et al., 1995]; human interleukin-5 [Rose et al., 1992]; human parathyroid hormone [Rabbani et al., 1988; Hogset et al., 1990]; human gamma-interferon [Honda et al., 1989]). In addition retention of N-formyl methionine has been found in endogeneous *E. coli* proteins (Hauschild-Rogat, 1968; Marasco et al., 1984; Milligan and Koshland,
- 20 1990).

Since N-formylated peptides are a major indicator of eubacterial infections for the mammalian immune system and are highly immunogenic, incomplete deformylation precludes, for example, the use of N-formylated preparations for therapeutic

25 purposes.

Several approaches to circumvent this problem have been proposed, e.g., expression in the presence of trimethoprim and thymidine (Sandman et al., 1995), overexpression of peptide deformylase in the host (US 6, 190, 902), expression as a

30 protein fusion either with an N-terminal peptide that can be removed in vitro by a specific protease or with an N-terminal leader peptide which is cleaved during

transport of the nascent protein in a non-cytoplasmatic compartment. Finally, the N-formyl group may also be removed by mild acid hydrolysis, or the fraction of the protein retaining N-formyl methionine may be separated from the correctly processed protein by purification procedures.

5

Each of these approaches has significant disadvantages. Addition of trimethoprim and thymidine is costly, requires manipulation of the culture that will express the recombinant protein, and may slow down growth of the host. Overexpression of peptide deformylase requires a stable plasmid construct in the host that has to be selected for; moreover, deformylation may be less than 100% effective. Expression of fusion proteins requires exact molecular constructions; chemical hydrolysis with acid may cause damage to the rest of the protein. Finally, none of these approaches guarantees a final preparation that is absolutely free of N-formylated peptides derived either from the recombinant protein or from contaminations with endogeneous host peptides.

15

The above mentioned drawbacks are solved if one could produce peptides in bacteria that are freed of the N-transformylation system. But, for bacteria that have evolved with this system for billions of year, removal of this system would normally result in death or serious impairment ultimately leading to organisms that are uncompetitive and genetically unstable. Indeed, when these modified bacteria are in contact with non modified bacteria they either recuperate the lost functional genetic elements or they simply disappear in favor of the more competitive natural bacteria.

20

One could also think that it would take billions of years of evolution to see emergence of bacteria devoid of the N-transformylation activity.

25

In connection with the invention, the N-transformylation system have been inactivated in bacteria having normally the N-transformylation system. Following a selective process, strains that are genetically stable and capable of competing with the natural bacteria have been obtained in only one month.

30

The invention opens new possibilities for obtaining new organisms that will constitute new species useful in all kind of industries by means of resurgent evolution.

5 Description

Therefore, in a first embodiment, the invention relates to a method for conducting resurgent evolution of microbial strains comprising the steps consisting of:

- a) irreversible alteration of the genome of a microbial clone;
- 10 b) cultivation of a vast population of a microbial clone as obtained in step a) during numerous generations under conditions allowing selection of accelerated proliferation not limited by the nutritional supply;
- c) isolation of descendant clones within the cultivated population of step b) on the basis of increased proliferation rate during, said clones having enhanced metabolic
- 15 activities compared to the microbial clones of step a) while still bearing the alteration of step a).

In this method, microbial strains can be bacteria such as *E. Coli*.

- 20 Steps b) and c) essentially consist of resurgent evolution, which means that the rate of proliferation of bacteria obtained after culturing during a prolonged period of time (about 1 month for *E. Coli*) is significantly increased compared to bacteria of step a).

- 25 For example, the rate of proliferation of bacteria obtained after resurgent evolution in step c) can be comparable to rate of proliferation of the natural bacteria.

This resurgence is the result of the acquisition of a succession of mutations which stabilized the evolution to reach a new specie or to break off with the phylogenic branch of the natural bacteria.

In a particular embodiment, the new specie is capable of competing with the natural bacteria. In this regards, the new specie is genetically stable even in presence of the natural bacteria, which means that the bacteria obtained after completion of the method cannot revert to the phenotype and genotype of the natural (initial) bacteria.

- 5 In other words, the new specie is stable in that it cannot genetically revert to the natural bacteria.

The new specie can be for example a humanized bacteria.

- 10 The successive mutations acquired by the bacteria of the new specie constitute tags that are genetically stable and form a particular branding for such new specie. The branding can originates from the metabolic modifications acquired during steps b) and c).

- 15 Step c) can be performed in minimal medium at 37°C or more, an important feature being that there is unlimited supply of nutriments.

- In addition, the isolation in step c) can be performed when the bacteria of step b) reach a plateau in the rate of proliferation. By repeating these steps, several maximum proliferation rates can be reached successively until the isolated clones display a rate which is satisfactory, for example a rate which is comparable to the
20 natural bacteria.

- In a specific embodiment, the alteration is the inactivation of at least one gene in step a). The inactivation can be a deletion, a mutation, or a substitution with other
25 sequences from other organisms.

- The gene can be the first gene coding for the Met-tRNAi transformylase. In this case, step a) can comprise the deletion of the entire def-first operon. As mentioned above, the natural bacteria can be *E. Coli*.

30

Therefore, in this case, the bacteria of step c) is devoid of N-formylating activities.

The invention is also directed to a method as defined above, wherein steps b) and c) are performed with a device comprising:

- a) at least a first and at least a second culture vessel (4,6) for receiving a culture (38);
- b) a gas source (12);
- c) a medium source (18);
- d) a source (20) for a sterilizing agent (21); and
- e) a conduit system with means for selectively connecting one of said two culture system (4 or 6) with said medium source (18) as well as said two culture vessels (4, 6) with each other and for selectively connecting said respective other culture vessel (4 or 6) with said source (20) for said sterilizing agent (21).

This device and the above numbers are fully explicated in WO 00/34433, more particularly in figure 1 which is incorporated by reference in the description.

15

In another embodiment, the invention is aimed at a mutated bacteria obtainable by the method defined above, wherein said bacteria constitutes a new specie that can not genetically revert to the natural bacteria.

- 20 In another embodiment, the invention is aimed at a mutated bacteria obtainable by the method defined above, wherein said bacteria belongs a phylogenic class which differs from the natural bacteria.

- 25 Such mutated bacteria can compete with the natural bacteria in terms of proliferation rate. It comprises several acquired mutations constituting tags leading to a new branding, said mutations being genetically stable even in presence of the natural bacteria.

- 30 The invention relates to a microbial strain comprising an irreversible alteration of its genome, while displaying an increased proliferation rate compared to the non-altered bacteria. In addition, this microbial strain can have enhanced metabolic activities or a different information treatment process.

The invention is also directed to a mutated bacteria which has been modified by the inactivation of at least one gene, wherein said bacteria have acquired mutations during provoked resurgent evolution leading to a genetically stable new specie. The
5 acquired mutations are stable and constitute tags leading to a new branding.

More particularly, the invention relates to a mutated bacteria comprising an inactivated Met-tRNA transformylase, wherein said bacteria acquired mutations during provoked resurgent evolution leading to a genetically stable new specie. Said
10 bacteria does not produce formyl-met peptides and is capable of competing with the natural bacteria in terms of proliferation rate.

The invention is aimed at a mutated bacteria consisting of strain β 2137 deposited at the CNCM on July 26, 2001 (Collection Nationale de Cultures de Microorganismes,
15 Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris cedex 15, France) under the accession number I-2707.

The above bacteria of the invention can be transformed with a vector comprising the coding sequence for a peptide or protein of interest. More particularly, they are non
20 formylated peptides or proteins.

As mentioned above, the present invention contemplates a mutated bacteria comprising an inactivated Met-tRNA transformylase, wherein said bacteria acquired mutations during provoked resurgent evolution leading to a genetically stable new
25 specie.

This bacteria is an E. coli strain with a primer methionine cycle similar to that in eucaryotic cells. This strain does non longer harbor the def-fmt operon encoding Met-tRNAi transformylase and polypeptide deformylase and thus can not N-formylate Met-tRNAi. Removal of N-formyl groups from expressed proteins by any
30 of the techniques described above is thus no longer required.

- The *fnt* and *def* genes from *E. coli* were previously isolated (Guillon et al., 1992; Mazel et al., 1994) and shown to be highly conserved among eubacteria (Mazel et al.,). Deletion mutants for either the *fnt* gene (Guillon et al., 1992) or the entire *def-fnt* operon (Mazel et al., 1994, D[*def-fnt*]) were created. The resulting mutants were reported to be severely impaired in growth. The *fnt* mutant has an 8.61-fold decreased growth rate at 37°C in rich medium and does not grow at 42°C (Guillon et al., 1992). The *def-fnt* mutant has a similarly decreased growth rate in minimal medium at 37°C, and growth is completely impaired in this medium at 42°C (). Whereas deletion of the *fnt* gene alone leaves the mutant bacteria viable, deletion of the *def* gene alone as well as re-introduction of the *fnt* gene into a *def-fnt* background is lethal (Mazel et al., 1994), demonstrating that essential bacterial proteins either have to be deformedylated, and/or that the initiator methionine has to be cleaved off in order to render these proteins functional.
- For the purpose of the present invention, a *def-fnt* deletion mutant was selected for enhanced growth rates under permanent proliferation in minimal medium at 37°C until its growth rate approximated that of the parent wild-type bacterium.
- Therefore, the invention is aimed at bacteria such as a eubacterium with altered translational mechanism such that it contains no *fnt* and *def* genes yet grows at wt rate. Said *E. coli* formyl-free strain is growing at temperatures higher than 37°C and can be used for the expression of recombinant proteins and peptides which are not contaminated with N-formylated peptides.
- The invention also relates to a method for provoking resurgent evolution of bacteria in which at least one gene has been inactivated comprising the steps consisting of:
- a) culturing said mutated bacteria in suspension in continuous proliferation state and constant cell density;
 - b) selecting of a subpopulation of bacteria on the basis of increased proliferation rate after a prolonged period of time during which said subpopulation acquired mutations

resulting in a resurging evolution; said mutated bacteria still bearing the initial mutation.

The initial mutation can consist of the inactivation of at least one gene or of part of all of an operon. The resurgent evolution allows the acquisition of successive mutations leading to a new genetically stable specie adapted to natural or artificial environments.

The invention also relates to a method for generating stable bacterial strains with modified information transfer process comprising the steps consisting of:

- 10 a) irreversible alteration of the genome of a microbial clone ;
- b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate;
- 15 c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a).

The term "modified information transfer" may refer to a non natural information treatment process ultimately leading to a novel form of life.

The invention also relates to a method for conducting microbial evolution leading to a change in the phylogenic classification comprising the steps consisting of:

- 20 a) irreversible alteration of the genome of a microbial clone ;
- b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate;
- 25 c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a).

The invention also relates to a method for generating a novel form of life comprising the steps consisting of:

- 30 a) irreversible alteration of the genome of a microbial clone ;

- b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate;
- c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a).

In the above methods, step b) can consist of the cultivation of a vast population of a microbial clone as obtained in step a) during numerous generations under conditions allowing selection of accelerated proliferation not limited by the nutritional supply;

And step c) can consist of the isolation of descendant clones within the cultivated population of step b) on the basis of increased proliferation rate during, said clones having enhanced metabolic activities compared to the microbial clones of step a) while still bearing the alteration of step a).

Figure legends

Fig. 1 : The primer methionine cycle in eubacteria (left) and archaea and eukaryotes (right) metG, met-tRNA synthetase ; *fmt*, met-tRNAi transformylase ; *def*, polypeptide deformylase ; map, methionine aminopeptidase ; aa, amino acid ; f, formyl ; pp, polypeptide. Modified after (3).

Fig. 2 : In vivo evolution of a D(*def-fmt*) mutant under permanent proliferation.. a, Cells were kept under permanent proliferation in minimal medium at 37°C. A turbidostat regime at 5x10⁸ cells/ml was applied. Growth rates are averaged over 24 h periods. Two independent runs are shown. b, Input (1) and evolved strains isolated during the process (2, 3, 4 ; c.f., numbers and open circles in a) were grown on minimal agar for 36 h at 37°C.

Fig. 3 : In vivo evolution of a D(*def-fmt*) mutant at increased mutation rates. Two independent runs are shown.

Fig. 4 : Emergence and selection of adhesive variants in a conventional turbidostat, and counter-selection of adhesive variants by the device described in WO 00/34433. Starting at point 1, adhesive variants were allowed to compete with cells in suspension, periodic destruction of static variants was re-established at point 3; a, Growth rates of the populations as measured in batch culture. b, Adhesion of cell material to glass surfaces. Isolates (points 1 – 6 in a) were cultivated in glass tubes for 20 h at 37°C. Arrowheads point to material that accumulated on the surface during cultivation.

Example 1 : Selection of enhanced growth rate in the *def-fmt* mutant.

I- Materials and Methods

1.1 Strains

γ 2045

Our reference strain is γ 2045 :

Escherichia coli MG1655 $\Delta(def-fmt)::cat$, *dnaQ*::miniTn10 [Cm^R, Tc^R]

MG1655 is a wild-type K12 strain of *E. coli* (see EMBO J. (1994) 13:914-923) $\Delta(def-fmt)$ means deletion of the *def-fmt* operon, which encodes the polypeptide deformylase and the Met-tRNAi transformylase activities. This allele has been described (EMBO J. (1994) 13:914-923).

The writing *::cat* means the insertion of a *cat* (chloramphenicol acetyl-transferase) gene in the $\Delta(def-fmt)$ locus

dnaQ::miniTn10 means that the *dnaQ* gene (epsilon subunit of the DNA polymerase, the proof-reading subunit) is interrupted by the insertion of a minitransposon Tn10 which confers the tetracycline resistance

[Cm^R, Tc^R] means that the strain is resistant to chloramphenicol (25 micg/ml) and to Tetracycline (15 micg/ml).

This bacterial strain carries a deletion of the *def-fmt* operon and is consequently defective in the Met-tRNAi transformylase and polypeptide deformylase activities. This strain also carries *dnaQ* mutation and consequently shows a mutator phenotype. This strain is a derivative of β 2124 that has been selected to grow in minimal and complex nutrient media at 30°C, 37°C and 42°C with near wild-type rate (approximately 25 min in LB and approximately 80 min in MS minimal medium (Richaud (1993), J. Biol. Chem. 268:26827-26835) with mannitol as carbon source at final concentration 0.2% at 37°C). The original β 2124 strain shows a growth rate of approximately 200 min in MS minimal medium + mannitol at 37°C. γ 2045, the β 2124 derivative, was selected for enhanced growth rates under permanent proliferation in minimal medium at 37°C until its growth rate reached that of MG1655, the parent wild-type bacterium. The mutator phenotype can be rescued by complementation with a *dnaQ* wild type allele expressed either from a plasmid or from the chromosome, through an allele replacement in γ 2045.

β 2137

Our reference strain is β 2137:

Escherichia coli MG1655, Δ *fmt::cat* [44°C^S, Cm^R]

20

MG1655 is a wild-type K12 strain of *E. coli* (see EMBO J. (1994) 13:914-923)

Δ *fmt* means deletion of the *fmt* gene which encodes the Met-tRNAi transformylase activity. This allele has never been described, it is a Pst I deletion, internal to *fmt* (nucleotides 247 to 484).

25

The writing *::cat* means the insertion of a *cat* (chloramphenicol acetyl-transferase) gene at the PstI site of the deletion. The *cat* gene is identical to the one used for the construction of the Δ (*def-fmt*)::*cat* allele (see EMBO J. (1994) 13:914-923).

[44°C^S, Cm^R] means that the strain is thermosensitive and resistant to chloramphenicol (25 micg/ml).

30

This bacterial strain carries a deletion of the *fmt* gene and is consequently defective in the Met-tRNAi transformylase activity. This strain is a derivative of MG1655 that has a growth rate of approximately 200 min in MS minimal medium + mannitol at 37°C.

DATA:DEF (SEQ ID N°1):

MSVLQVLHIPDERLRKVKPVEEVNAEIQRIVDDMFETMYAEEGIGLAAT
10 QVDIHQRIIVIDVSENDRERLVLINPELLEKSGETGIEEGCLSIPEQRAL
VPRAEKVKIRALDRDGKPFLEADGLLAICIQHEMDHLVGKLFMDYLSPL
KQQRIRQKVEKLDRLKARA

def (gene) (SEQ ID N°2):

15 atgtcagttttgcaagtgttacatattccggacgagcggcttcgcaaagt
tgctaaaccggtagaagaagtgaatgcagaaattoacggtatcgtcgatg
atatgttcgagacgatgtacgcagaagaaggtattggcctggcggcaacc
caggttgatatccatcaacgtatcattgttattgatgttcggaaaaccg
tgacgaacggctagtgttaataatccagagcttttagaaaaagcggcg
20 aaacaggcattgaagaaggttgccctgtcgatccctgaacaacgtgcttta
gtgccgcgcgcagagaaagttaaaattcgcgcccttgaccgcgacggtaa
accatttgaactggaagcagacggctcgttagccatctgtattcagcatg
agatggatcacctggtcggcaaaactgtttattgattatctgtcacccgtg
aacaacaacgtattcgtcagaaagttgaaaaactggatcgctcgaagc
25 ccgggcttaa

FMT (SEQ ID N°3):

MSESLRRIIFAGTPDFAARHLDALSSGHNVVGVFTQPDPRAGRGKKLMPSF
VKVLAEEKGLPVFPVSLRPQENQQLVAELQADVMVVVAYGLILPKAVLE
30 MPRLGCINVHGSLLPRWRGAAPIQRSWAGDAETGVTIMQMDVGLDTGDM
LYKLSCPITAEDTSGTLYDKLAELGPQGLITTLKQLADGTAKPEVQDETL

VTYAEKLSKEEARIDWSLSAAQLERCIRAFNPWPMWSWLEIEGQPVKVWKA
 SVIDTATNAAPGTILEANKQGIQVATGDGILNLLSLQFAGKKAMSAQDLL
 NSRREWFVPGNRLV

5 *fmt* (gene) (SEQ ID N°4):

gtgtcagaatcactacgtattatTTTTGCGGGTACACCTGACTTTGCAGC
 GCgtcatctcgacgcgctgttgcTcttctggTcataacgTcgTtgGcgTgt
 TcaccagccagaccgaccggcaggacgcggTaaaaaactgatgccagc
 ccggtTaaagTtctggctgaggaaaaagTctgcccgtTTTTcaacctgt
 10 TtcctcgctccacaagaaaaccagcaactggTcgccgaactgcagcgTg
 atgttatggTcgTcgTcgctatggTttaaTtctgccgaagcagTgctg
 gagatgccgcgTcttggctgtatcaacgTtcatggTtcactgTgccacg
 ctggcgcgTgctgcaccaatccaacgTcactatggcgggTgatgcag
 aaactggTgtgaccattatgcaaatggatgTcggtttagacaccggTgat
 15 atgctctataagctctcctgcccGATTactgcagaagataccagTggtac
 gctgtacgacaagctggcagagcttggcccacaaggcttatcaccagT
 TgaaacaactggcagacggcaccggcgaaccagaagTtcaggacgaaact
 ctTgtcacttacgcccGagaagTtgagTaaagaagaagcgTatttgactg
 gtCactTtcggcagcacagcttgaaCgctgcattcgcgcttTcaatccat
 20 ggccaatgagctggctggaaattgaaggacagccggTtaaagTctggaaa
 gcatcggtcattgatacggaaccaacgctgcaccaggaacgatcctTga
 agccaacaacaaggcattcaggTtgcgactggTgatggcatcctgaacc
 TgtctcgtttacaacctgcgggTaaagaaagcgatgagcgcgcaagacctc
 ctgaactctcgtcggaatggTttgttcgggcaaccgTctggTctga
 25

1.2 Media

Strains were cultivated in minimal medium (4 mM citrate x H₂O, 1 mM MgSO₄ x 7
 30 H₂O, 10 mM NH₄Cl, 0.2% w/v mannitol and 1 ml/l NTA-trace elements*) at 37°C.
 Solid media contained 1.8% agar.

(*NTA-trace elements x 1000)

Component	Concentration (M)
Nitrilotriacetic acid	10^{-2}
$\text{CaCl}_2 \times 2 \text{ H}_2\text{O}$	3×10^{-3}
$\text{FeCl}_3 \times 6 \text{ H}_2\text{O}$	2×10^{-3}
$\text{MnCl}_2 \times 4 \text{ H}_2\text{O}$	10^{-3}
ZnCl_2	10^{-3}
H_3BO_3	3×10^{-4}
$\text{CrCl}_3 \times 6 \text{ H}_2\text{O}$	3×10^{-4}
$\text{CoCl}_2 \times 6 \text{ H}_2\text{O}$	3×10^{-4}
$\text{CuCl}_2 \times 2 \text{ H}_2\text{O}$	3×10^{-4}
$\text{NiCl}_2 \times 6 \text{ H}_2\text{O}$	3×10^{-4}
$\text{Na}_2\text{MoO}_4 \times 2 \text{ H}_2\text{O}$	3×10^{-4}
$\text{Na}_2\text{SeO}_3 \times 5 \text{ H}_2\text{O}$	3×10^{-4}

1.3 Continuous cultivation

- 5 Populations of *E. coli* β 2124 or β 2116 were kept under continuous proliferation at 37°C in the device described by Mutzel and Marlière in WO 00/34433.

Culture volume was 26.0 ml. A turbidostat regime was applied, keeping the $\text{OD}_{600 \text{ nm}}$ of the culture at ca. 1.0. Growth rates calculated from the culture volume (V) and the
 10 flow of fresh medium (W) according to $R=W/V \cdot 1/\ln 2$ were averaged over 24 h periods. Calculated growth rates were compared with growth rates obtained from batch cultures.

Stocks were prepared by mixing 0.1 ml DMSO with 1 ml samples withdrawn from
 15 the device and kept at -70°C

20 II- Results : An *E. coli* strain for expression of N-formyl-free polypeptides

In eubacteria peptide synthesis is initiated at methionine start codons which are read by N-formyl methionine tRNA. Prior to translation initiation, the methionyl moiety of the charged tRNA is N-formylated by the action of Met-tRNAi transformylase. The N-formyl group is removed from the native protein by polypeptide deformylase, and the initiator methionine can then be cleaved off by methionine aminopeptidase, completing the primer methionine cycle (fig. 1 a). In contrast, archaea and eukaryotes have a primer methionine cycle devoid of N-formylating and deformylating activities (fig. 1 b).

- 10 Expression of eukaryotic proteins in eubacterial hosts often results in the production of recombinant proteins that retain an N-terminal formylmethionyl residue. Since N-formylated peptides are highly immunogenic, incomplete deformylation precludes, for example, their use for therapeutic purposes. Several approaches to circumvent this problem have been proposed, e.g., expression in the presence of trimethoprim and thymidine (Sandman, K., Gryling, R.A. and Revve, J.N. (1995) : Improved N-terminal processing of recombinant proteins synthesized in *E. coli*. *Biotechnology* 13, 504-506) or overexpression of peptide deformylase in the host (Warren, W.C., Bentle, K.A., Schlittler, M.R., Schwane, A.C., O'Neil, J.P. and Bogosian, G. (1996) : Increased production of peptide deformylase eliminates retention of formylmethionine in bovine somatotropin overproduced in *E. coli*. *Gene* 174, 235-238).

The inventors have opted for a radical solution, simplifying the primer methionine cycle in *E. coli* by deletion of the *def-fmt* operon that encodes polypeptide deformylase and met-tRNAi transformylase, and improving the resulting, crippled strain by selecting for increasing growth rates (and therefore improved rates of protein synthesis) under permanent proliferation in suspension.

- 25 The inventors have isolated the *def* and *fmt* genes from *E. coli* and created a deletion mutant (D[*def-fmt*]) devoid of both genes (Mazel, D., Pochet, S. and Marlière, P. (1994) : Genetic characterization of polypeptide deformylase, a distinctive enzyme

of eubacterial translation. EMBO J. 13, 914-923). The resulting strain was found to be viable, however its growth rate was dramatically reduced, from 0.9 per h to 0.25 per h in minimal medium at 37°C.

- 5 Protein synthesis in living cells is dependent on the concerted action of a complex assembly of the protein and rRNA constituents of ribosomes and a host of factors catalyzing aminoacylation of tRNAs, initiation, elongation and termination of translation as well as maturation of nascent polypeptides. N-terminal formylation is among the most conserved features that distinguish eubacteria from archaea and
10 eukaryotes. Removing the enzymes that catalyze the corresponding reactions is therefore expected to remove the efficiency of protein synthesis far from its wild-type optimum. Evolutionary resurrection from this type of genetic injury will require multiple adaptive mutations to render the bacterial translation machinery more similar to that found in eukaryotes. State-of-the-art technologies for directed
15 evolution ex vivo are unable to predict and select the adaptive mutations that would re-establish wild-type protein synthesis rates in a D(*def-fmt*) background.

- In vivo evolution of the D(*def-fmt*) mutant under permanent proliferation in suspension in a turbidostat regime yields variants with increasing growth rate,
20 approximating wild-type growth rate after about 1 month (ca. 300 generations) of permanent selection (fig. 2). We observed a drastically increases biomass production of evolved derivatives tested for growth on minimal agar as compared to the input D(*def-fmt*) mutant. Stepwise increases in the growth rate of the evolving population result in selection and fixation of successive adaptive mutations.
- 25 We have evidence that the protein met-tRNA synthetase, certain ribosomal proteins, initiation factor 2, and methionine aminopeptidase are altered in the output strains.

- The evolutionary process can be accelerated by increasing variation in the population (fig. 3). When mutation rates in the population under selection were increased by a
30 factor of about 1,000, wild-type growth rates were approximated within about half the time required for the process shown in fig. 2.

Current technology for continuous proliferation of cells in suspension suffers a major drawback, selection of adhesive variants which stick to inner surfaces of the device and escape the selective pressure imposed by continuous or conditional dilution

5 (Chao, L. and Ramsdell, G. (1985) : The effects of wall populations on coexistence of bacteria in the liquid phase of chemostat cultures. J. Gen. Microbiol. 131, 1229-1236). In principle, this can be avoided by serial subculture of cells in suspension (Lenski, R.E. and Travisano, M. (1994) : Dynamics of adaptation and diversification : A 10,000-generation experiment with bacterial populations. Proc. Natl. Acad. Sci.

10 USA 91, 6808-6814), a technique where cells in suspension are frequently transferred into fresh culture vessels (i.e., surfaces are periodically discarded), creating a selective disadvantage for static variants. At an industrial scale, serial subculture technology has not been systematically exploited because it is laborious and requires absolute sterility during transfers.

15 Automated technology for the permanent proliferation of populations of cells exclusively in suspension has been proposed in WO 00/34433. During the course of an experiment similar to that shown in fig. 3, operation of the device was manipulated such that static, adhesive variants were no longer destroyed and could

20 freely compete with cells in suspension. Highly adhesive variants accumulated rapidly (data not shown). In parallel, the growth rate of the population decreased, demonstrating that these static variants are not subject to the selective pressure imposed on the cells in suspension. When proper operation of the device was re-established, these variants were rapidly and effectively eliminated from the evolving

25 population.

Conclusion

The automated device described in WO 00/34433 is the first operational apparatus

30 which allows permanent proliferation of living cells under defined, selective conditions and is particularly suited for the resurgent evolution of mutated bacteria.

The automated process frequently and effectively destroys static variants in any part of the device, overcoming the primary obstacle to continuous proliferation of cells in suspension for indefinite periods of time.

5

We have created derivatives of *E. coli* with a primer methionine cycle similar to that in eukaryotic cells. The strains will allow for expression of N-formyl-free polypeptides in *E. coli*.

- 10 Evolved microbial strains with unique genetic and metabolic imprints will serve as ancestors for the diversification of lines of industrially fit micro-organisms.

REFERENCES

- Bogosian, G., et al., (1989) Biosynthesis and incorporation into protein of norleucine
5 by *Escherichia coli* J. Biol. Chem. 264:531-539.
- Clogston, C. L., Hsu, Y. R., Boone, T. C. and Lu, H. S.: Detection and quantitation
of recombinant granulocyte colony-stimulating factor charge isoforms: comparative
analysis by cationic-exchange chromatography, isoelectric focusing gel
10 electrophoresis, and peptide mapping. Anal. Biochem. 202 (1992) 375-383.
- Dong, M. S., Guo, Z., Philips, D. R., Bell, L. C., Howard, E., Blair, I. A., Gillam, E.
M. J., Baba, T., Waterman, M. R. and Guengerich, F. P.: Retention of N-
formylmethionine in recombinant bacterial cytochrome P450 enzymes containing the
15 N-terminal sequence MALLAVFL. FASEB J. 9 (1995) A1486.
- Guillon, J. M., Mechulam, Y., Schmitter, J. M., Blanquet, S. and Fayat, G.:
Disruption of the gene for Met-tRNA-fMet formyltransferase severely impairs
growth of *Escherichia coli*. J. Bacteriol. 174 (1992) 4294-4301.
20
- Hauschild-Rogat, P.: N-formylmethionine as a N-terminal group of *E. coli* ribosomal
protein. Mol. Gen. Genet. 102 (1968) 95-101.
- Hogset, A., Blingsmo, O. R., Gautvik, V. T., Saether, O., Jacobsen, P. B.,
25 Gordeladzo, J. O., Alestrom, P. and Gautvik, K. M. Expression of Human
Parathyroid Hormone In *Escherichia Coli*. Biochemical and Biophysical Research
Communications 166:1 (1990) 50-60.
- Honda, S., Asano, T., Kajio, T., and Nishimura, O. *Escherichia coli*-Derived Human
30 Interferon- γ . with Cys-Tyr-Cys at the N-Terminus is Partially N-sup..alpha. -
Acylated. Archives of Biochemistry and Biophysics 269 (1989) 612-622.

- Marasco, W. A., Phan, S. H., Kruttsch, H., Showell, H. J., Feltner, D. E., Naim, R., Becker, E. L. and Ward, P. A.: Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by
5 *Escherichia coli*. *J. Biol. Chem.* 259 (1984) 5430-5439.
- Mazel, D., Pochet, S. and Marliere, P.: Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. *EMBO J.* 13 (1994) 914-923.
- 10 Milligan, D. L. and Koshland, Jr., D. E.: The amino terminus of the aspartate chemoreceptor is formylmethionine. *J. Biol. Chem.* 265 (1990) 4455-4460.
- Rabbani, S. A., Yasuda T., Bennett H. P. J., Sung, W. L., Zahab, D. M., Tam, C. S.
15 Goltman, D., and Hendy, G. N. Recombinant Human Parathyroid Hormone Synthesized in *Escherichia coli*. *Journal of Biological Chemistry* 263:3 (1988) 1307-1313.
- Rose, K., Regamey, P., Anderegg, R., Wells, T., Proudfoot, A., Human interleukin-5
20 expressed in *Escherichia coli* has N-terminal modifications. *Biochem J.* 286 (1992) 825-828.
- Sandman, K., Grayling, R. A., and Reeve, J. N. Improved N-terminal Processing of Recombinant Proteins Synthesized in *Escherichia coli*. *Biotechnology* 13 (1995)
25 504-506.
- Specht, B., Oudenampsen-Kruger, E., Ingendoh, A., Hillenkamp, F., Lezius, A. G. and Spener, F.: N-terminal variants of fatty acid-binding protein from bovine heart overexpressed in *Escherichia coli*. *J. Biotechnol.* 33 (1994) 259-269.
- 30

Sugimoto, S., Yamaguchi, K. and Yokoo, Y.: Isolation and characterization of recombinant eel growth hormone expressed in *Escherichia coli*. *J. Chromatog.* 515 (1990) 483-494.

CLAIMS

- 5 1. A method for generating a novel form of life comprising the steps consisting of:
a) irreversible alteration of the genome of a microbial clone ;
b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate;
- 10 c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a).
2. A method for conducting microbial evolution leading to a change in the phylogenic classification comprising the steps consisting of:
- 15 a) irreversible alteration of the genome of a microbial clone ;
b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate;
- 20 c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a).
3. A method for generating stable bacterial strains with modified information transfer process comprising the steps consisting of:
- a) irreversible alteration of the genome of a microbial clone ;
- 25 b) cultivation of a vast population of microbial cells originating from the altered clone obtained in step a) during numerous generations under conditions allowing selection for a higher and stable proliferation rate;
- c) isolation of descendant clones within the cultivated population of step b) still bearing the alteration of step a).

4. A method according to one of claims 1 to 3, wherein step b) consists of the cultivation of a vast population of a microbial clone as obtained in step a) during numerous generations under conditions allowing selection of accelerated proliferation not limited by the nutritional supply.
- 5
5. A method according to one of claims 1 to 4, wherein step c) consists of isolating descendant clones within the cultivated population of step b) on the basis of increased proliferation rate during, said clones having enhanced metabolic activities compared to the microbial clones of step a) while still bearing the alteration of step
- 10 a).
6. A method according to one of claims 1 to 5, wherein the rate of proliferation of bacteria obtained after resurgent evolution in step c) is significantly increased compared to bacteria of step a).
- 15
7. A method according one of claims 1 to 5, wherein the rate of proliferation of bacteria obtained after resurgent evolution in step c) is comparable to rate of proliferation of the natural bacteria.
- 20
8. A method according to one of claims 1 to 5, wherein bacteria of step c) have acquired a succession of mutations which stabilized the evolution to reach a new specie.
- 25
9. A method according to claim 8, wherein the new specie is capable of competing with the natural bacteria.
10. A method according to claim 8, wherein the new specie is genetically stable even in presence of the natural bacteria.
- 30
11. A method according to one of claims 1 to 10, wherein bacteria of the new specie can not genetically revert to the natural bacteria.

12. A method according to one of claims 1 to 11, wherein bacteria of the new specie are humanized bacteria.
- 5 13. A method according to one of claims 1 to 12, wherein the successive mutations acquired by the bacteria of the new specie constitute tags that are genetically stable and form a particular branding for such new specie.
14. A method according to one of claims 1 to 13, wherein step c) is performed in
10 minimal medium at 37°C.
15. A method according to one of claims 1 to 14, wherein the inactivated gene in step a) is the *fnt* gene coding for the Met-tRNAⁱ transformylase.
- 15 16. A method according to one of claims 1 to 15, wherein step a) comprises the deletion of the entire *def-fnt* operon.
17. A method according to one of claims 1 to 16, wherein the bacteria is *E. Coli*.
- 20 18. A method according to one of claims 1 to 17, wherein the bacteria of step c) is devoid of N-formylating activities.
19. A method according to one of claims 1 to 18, wherein steps b) and c) are performed with a device comprising:
- 25 a) at least a first and at least a second culture vessel (4,6) for receiving a culture (38);
b) a gas source (12);
c) a medium source (18);
d) a source (20) for a sterilizing agent (21); and
30 e) a conduit system with means for selectively connecting one of said two culture system (4 or 6) with said medium source (18) as well as said two culture vessels (4,

6) with each other and for selectively connecting said respective other culture vessel (4 or 6) with said source (20) for said sterilizing agent (21).

20. A mutated bacteria obtainable by the method of one of claims 1 to 19, wherein said bacteria constitutes a new specie that can not genetically revert to the natural bacteria.

21. A mutated bacteria according to claim 20, which is capable of competing with the natural bacteria.

10

22. A mutated bacteria according to claim 20, which comprises several acquired mutations constituting tags leading to a new branding, said mutations being genetically stable even in presence of the natural bacteria.

15 23. A mutated bacteria which has been modified by the inactivation of at least one gene, wherein said bacteria have acquired mutations during provoked resurgent evolution leading to a genetically stable new specie.

20 24. A mutated bacteria according to claim 23, wherein the acquired mutations are stable and constitute tags leading to a new branding.

25 25. A mutated bacteria comprising an inactivated Met-tRNA transformylase, wherein said bacteria acquired mutations during provoked resurgent evolution leading to a genetically stable new specie.

25

26. A mutated bacteria according to claim 25, wherein said bacteria is capable of competing with the natural bacteria in terms of proliferation rate rate.

30 27. A mutated bacteria according to one of claims 25 to 26, wherein said bacteria does not produce formyl-met peptides.

28. A mutated bacteria according to one of claims 25 to 27, wherein said bacteria is strain β 2137 deposited at the CNCM under the accession number I-2707.

5 29. A mutated bacteria according to one of claims 25 to 28, wherein said bacteria is transformed with a vector comprising the coding sequence for a peptide or protein of interest.

30. Use of a bacteria according to one of claims 25 to 29 for the production of non
10 formylated peptides or proteins.

31. A method for provoking resurgent evolution of bacteria in which at least one gene has been inactivated comprising the steps consisting of:

- 15 a) culturing said mutated bacteria in suspension in continuous proliferation state and constant cell density;
b) selecting of a subpopulation of bacteria on the basis of increased proliferation rate after a prolonged period of time during which said subpopulation acquired mutations resulting in a resurging evolution; said mutated bacteria still bearing the initial mutation.

20 32. A method according to claim 31, wherein the initial mutation consist of the inactivation of at least one gene or of part of all of an operon.

25 33. A method according to claim 31, wherein the resurgent evolution allows the acquisition of successive mutations leading toward a new genetically stable specie adapted to natural or artificial environments.

1 / 4

Figure 1a






Figure 1b




2 / 4

Figure 2




3 / 4

Figure 3



4 / 4

Figure 4



SEQUENCE LISTINGDEF (SEQ ID N°1):

MSVLQVLHIFDERLRKVAKPVEEVNAEIQRIVDDMFETMYAEEGIGLAAT
QVDIHQRIIVIDVSENDRERLVLINPELLEKSGETGIEGCLSIPEQRAL
VPRAEKVKIRALDRDGKPFLEADGLLAICIQHEMDHLVGKLFMDYLSPL
KQQRIRQKVEKLDRLKARA

def (gene) (SEQ ID N°2):

atgtcagtttttgcaagtgttacatattccggacgagcggttcgcaaagt
tgctaaaccggtagaagaagtgaatgcagaaattcagcgatcgtcgatg
atatgttcgagacgagtacgcagaagaaggtattggcctggcggaacc
caggttgatatccatcaacgtatcattgttattgatgtttcgaaaaaccg
tgacgaacggctagtgttaataatccagagcttttagaaaaagcggcg
aaacaggcattgaagaaggttgctgtcgatccctgaacaacgtgcttta
gtgcgcgcgcgagagaaagttaaaattcgcgcccttgaccgcgacggtaa
accatttgaaactggaagcagacggctctgttagccatctgtattcagcatg
agatggatcacctggtcggcaaacgtttattgattatctgtccaccgctg
aaacaacaacgtattcgtcagaaagttgaaaaactggatcgtctgaaagc
ccgggcttaa

FMT (SEQ ID N°3):

MSESLRIRIFAGTPDFAARHLDALSSGHNVVGVFTQPDPRPAGRKKLMPSF
VKVLAEEKGLPVFQPVSLRPQENQQLVAELQADVMVVVAYGLILPKAVLE
MPRLGCINVHGSLLPRWRGAAPIQRSLWAGDAETGVTIMQMDVGLDTGDM
LYLKSCPITAEDTSGTLYDKLAELGPQGLITTLKQLADGTAKPEVQDETL
VTYAEKLSKEEARIDWSLSAAQLERCIRAFNFPWMSWLEIEGQPVKVVKA
SVIDTATNAAPGTILEANKQGIQVATGDGILNLLSLQPAGKKAMSAQDLL
NSRREWFVPGNRLV

fnt (gene) (SEQ ID N°4):

gtgtcagaatcactacgtattatTTTTGCGGGTACACCTGACTTTGCAGC
gcgtcatctcgacgcgctgttgctctctgggtcataacgtcgttggcgtgt
tcacccagccagaccgacggcaggacgcggtaaaaaactgatgccagc

ccggttaaagttctggtgagggaaaaggtctgccggttttcaacctgt
ttccctgcgtccacaagaaaaccagcaactggtcgccgaactgcaggctg
atgttatggtcgtcgtcgctatggtttaattctgccgaagcagtgctg
gagatgccgcgtcttggtgtatcaacgttcatggttactgctgccacg
ctggcgcggtgctgcaccaatccaacgctcactatggcggtgatgcag
aaactggtgtgaccattatgcaaatggatgtcggttagacacgggtgat
atgctctataagctctcctgccgattactgcagaagataccagtgttac
gctgtacgacaagctggcagagcttggccacaagggttatcaccacgt
tgaaacaactggcagacggcacggcgaaaccagaagttcaggacgaaact
cttgctacttacgcgagaagttgagtaaagaagaagcgcgtattgactg
gtcactttcggcagcacagcttgaacgctgcattcgcgctttcaatccat
ggccaatgagctggtggaattgaaggacagccggttaaagctgga
gcatcggtcattgatacggcaaccaacgctgcaccaggaaacgatacctga
agccaacaaacaaggcattcaggttgcgactggtgatggcatcctgaacc
tgctctcgttacaacctgcgggtaagaaagcgatgagcgcgcaagacctc
ctgaactctcgtcggaatggtttgtccgggcaaccgtctggtctga

INTERNATIONAL SEARCH REPORT

 International Application No.
 PCT/IB 02/03398

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12N15/67

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category * Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

X	WO 00 34433 A (MUTZEL RUPERT ;MARLIERE PHILIPPE (FR); PASTEUR INSTITUT (FR)) 15 June 2000 (2000-06-15) cited in the application	1-14, 17, 19-24, 26, 31-33
Y	the whole document	15, 16, 18, 25, 27-30

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

 **A* document defining the general state of the art which is not
 considered to be of particular relevance
 **E* earlier document but published on or after the international
 filing date

 **L* document which may throw doubts on priority claim(s) or
 which is cited to establish the publication date of another
 citation or other special reason (as specified)

 **O* document referring to an oral disclosure, use, exhibition or
 other means

 **P* document published prior to the international filing date but
 later than the priority date claimed

 **T* later document published after the international filing date
 or priority date and not in conflict with the application but
 cited to understand the principle or theory underlying the
 invention

 **X* document of particular relevance; the claimed invention
 cannot be considered novel or cannot be considered to
 involve an inventive step when the document is taken alone

 **Y* document of particular relevance; the claimed invention
 cannot be considered to involve an inventive step when the
 document is combined with one or more other such docu-
 ments, each combination being obvious to a person skilled
 in the art

**Z* document member of the same patent family

Date of the actual completion of the international search

11 November 2002

Date of mailing of the international search report

26/11/2002

 Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2240, Tx. 51 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Schwachtgen, J-L

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/IB 02/03398

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VULIC M ET AL: "Mutation, recombination, and incipient speciation of bacteria in the laboratory." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 22 JUN 1999, vol. 96, no. 13, 22 June 1999 (1999-06-22), pages 7348-7351, XP002220212 ISSN: 0027-8424	1-14, 17, 20-24, 26, 31-33
Y	the whole document	15, 16, 18, 25, 27-30
Y	MAZEL D ET AL: "GENETIC CHARACTERIZATION OF POLYPEPTIDE DEFORMYLASE, A DISTINCTIVE ENZYME OF EUBACTERIAL TRANSLATION" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 4, 15 February 1994 (1994-02-15), pages 914-923, XP002043973 ISSN: 0261-4189 cited in the application the whole document	15, 16, 18, 25, 27-30

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/03398

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0034433	A	15-06-2000	
		DE 19856136 A1	08-06-2000
		AU 1779900 A	26-06-2000
		WO 0034433 A1	15-06-2000
		EP 1135460 A1	26-09-2001
		JP 2002531114 T	24-09-2002